Download Free Antiprogesterone Steroid Ru 486 Book in PDF and EPUB Free Download. You can read online Antiprogesterone Steroid Ru 486 and write the review.

Advances in basic biological research have proceeded rapidly in recent years. The fields of molecular genetics and immunology have experienced dramatic breakthroughs, capturing the imagination of both the scientific community and the general public. With less public notice, receptor biology has brought a cascade of new discoveries and insights. The entire science of pharmacology has been virtually rewritten in terms of receptor phenomenology. In particular, the discovery of specific receptors for steroid and protein hormones has been of seminal importance. With this new information, we have advanced our understanding of the mechanism and specifity of hormone action. We can now explain how hormones interact selectively with specific target cells and how hormones alter biochemical events within the target cells. These facts have already impacted on applied problems of clinical medicine, particularly in diagnosis and treatment of cancer and some metabolic diseases. Now, a new and important application of basic receptor biology and chemistry looms ahead. Within a few short years since the discovery of the progesterone receptor, chemists have synthesized molecules with a greater affinity for the receptor than progesterone itself and which, while occupying the receptor, fail to trigger the events which transform a target cell from the unstimulated to the stimulated state. This is the basis of the competitive inhibitory action of the anti-progestational agent, synthesized by the chemists at Roussel Uc1af, Paris, and designated RU 486.
Mifepristone (RU486), the first clinically available antiprogestin, has generated great interest since its discovery in the early 1980s. Today, it is recognized that mifepristone, along with other antiprogestins, has a potentially significant therapeutic role in human health and disease, with likely applicability to a variety of pregnancy-related conditions (e.g., management of labor) and to contraception, endometriosis, and cancer, among others. But because mifepristone has been studied and used most widely as a means of nonsurgical abortion, political issues have thus far limited research on the drug and prevented its introduction into the U.S. market. This book provides an unbiased evaluation of current knowledge about both the fundamental nature of antiprogestins as well as their possible use in treating numerous diseases and conditions, and it contains recommendations for future research.
Bovine Reproduction is a comprehensive, current reference providing information on all aspects of reproduction in the bull and cow. Offering fundamental knowledge on evaluating and restoring fertility in the bovine patient, the book also places information in the context of herd health where appropriate for a truly global view of bovine theriogenology. Printed in full color throughout, the book includes 83 chapters and more than 550 images, making it the most exhaustive reference available on this topic. Each section covers anatomy and physiology, breeding management, and reproductive surgery, as well as obstetrics and pregnancy wastage in the cow. Bovine Reproduction is a welcome resource for bovine practitioners, theriogenologists, and animal scientists, as well as veterinary students and residents with an interest in the cow.
Written by the foremost authority in the field, this volume is a comprehensive review of the multifaceted phenomenon of hepatotoxicity. Dr. Zimmerman examines the interface between chemicals and the liver; the latest research in experimental hepatotoxicology; the hepatotoxic risks of household, industrial, and environmental chemicals; and the adverse effects of drugs on the liver. This thoroughly revised, updated Second Edition features a greatly expanded section on the wide variety of drugs that can cause liver injury. For quick reference, an appendix lists these medications and their associated hepatic injuries. Also included are in-depth discussions of drug metabolism and factors affecting susceptibility to liver injury.
Featuring more than 4100 references, Drug-Induced Liver Disease will be an invaluable reference for gastroenterologists, hepatologists, family physicians, internists, pathologists, pharmacists, pharmacologists, and clinical toxicologists, and graduate and medical school students in these disciplines.
This is the very first book to deal with sex and gender differences in drug therapy - an increasingly recognized medical need. It starts with an overview on S/G in clinical syndromes and a documentation of the medical and socioeconomic damage caused by gender specific adverse drug effects. Part I covers S/G differences in pharmacokinetics. Researchers will be satisfied by the detailed discussion of the mechanisms of S/G differences in drug effects that represents cutting edge science and includes interaction of drugs with sex hormones, genomic and epigenetic mechanisms. It also covers S/G in drug development, in animal models and clinical development and S/G in drug prescriptions. Part II targets S/G differences in drug effects in cardiovascular, pulmonary, CNS, neuromuscular, neuropsychiatric and metabolic diseases, in cancer, inflammation, and rheumatic diseases, in bacterial and retroviral infections, thrombosis, embolism. New drugs will be discussed.
Annotation. An award-winner when first published, this book has become a classic text for health activists and feminists interested in the complexities of how drugs are developed, marketed and sold to women around the world. In this book the authors review the unusual history of the French abortion pill, RU 486 (mifepristone). They scrutinize the science and politics from inception through to its use on women. Is RU 486 a miracle drug for abortion that is a safe and effective alternative to conventional abortion procedures? Does it privatise and de-medicalise the abortion experience? Is its availability a victory for women? Is RU 486 safe for use in Third World countries and remote rural areas? Who benefits from chemical abortion and how does RU 486 affect existing abortion services? The authors argue that the positive claims made for RU 486 (mifepristone) are filled with myths and misconceptions. RU 486 used on its own is a failed abortifacient and needs the addition of a prostaglandin, a dangerous drug. But the success'rates of the drug cocktail RU 486/prostaglandin remain at 92 to 95 per cent compared with 98 to 99 per cent for suction abortions. Suction abortions, which are best done with a local anaesthetic, involve no harmful drugs and are completed in 30 minutes. By contrast, RU 486/PG abortions last for days, sometimes weeks. Heavy bleeding, transfusions, vomiting, severe pain and infection are among the unpredictable adverse effects. Women have died from sepsis and cardiovascular events. RU 486/PG abortion benefits the medical profession, drug companies and government health economies. Through painstaking research and analysis the authors uncover the truth that chemical abortion is ill-conceived and unethical. They caution that low-tech abortion services are under threat as the mainstream hails RU 486 abortion as safe and effective'which it is not.
The "contraceptive revolution" of the 1960s and 1970s introduced totally new contraceptive options and launched an era of research and product development. Yet by the late 1980s, conditions had changed and improvements in contraceptive products, while very important in relation to improved oral contraceptives, IUDs, implants, and injectables, had become primarily incremental. Is it time for a second contraceptive revolution and how might it happen? Contraceptive Research and Development explores the frontiers of science where the contraceptives of the future are likely to be found and lays out criteria for deciding where to make the next R&D investments. The book comprehensively examines today's contraceptive needs, identifies "niches" in those needs that seem most readily translatable into market terms, and scrutinizes issues that shape the market: method side effects and contraceptive failure, the challenge of HIV/AIDS and other sexually transmitted diseases, and the implications of the "women's agenda." Contraceptive Research and Development analyzes the response of the pharmaceutical industry to current dynamics in regulation, liability, public opinion, and the economics of the health sector and offers an integrated set of recommendations for public- and private-sector action to meet a whole new generation of demand.